Wolpin, B. M., Wainberg, Z. A., Garrido-Laguna, I., Manji, G. A., Spira, A. I., Azad, N. S., Pant, S., Zhang, Y., Trang, J., Salman, Z., O'Reilly, E. M. (2025). Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4230